Coexistence of fibromyalgia and post-polio syndrome in persons with prior poliomyelitis in Turkey: the relations with symptoms, polio-related impairments, and quality of life

Latifoglou, Emre; Çınar, Ece; Tanıgör, Göksel; On, Arzu Yağız

doi:10.1080/09638288.2022.2127931

Cited by 3 publications

(6 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If, for example, mechanical hyperalgesia/allodynia associated with PPS were to be confirmed in a future, larger study this might strengthen the theory of sensitization as part of the pain seen in PPS. This could possibly also give further insights into the fact that it appears to be more frequent in patients with PPS that they also fulfil the criteria of concomitant fibromyalgia with generalized musculoskeletal pain ( 4 , 38 ).…”

Section: Discussionmentioning

confidence: 96%

Post-polio syndrome – somatosensory dysfunction and its relation to pain: a pilot study with quantitative sensory testing

Dahlgren,

Borg,

Melin

2024

JRM

View full text Add to dashboard Cite

Objective: To explore and characterize somatosensory dysfunction in patients with post-polio syndrome and chronic pain, by conducting examinations with Quantitative Sensory Testing. Design: A cross-sectional, descriptive, pilot study conducted during 1 month. Subjects/patients: Six patients with previously established post-polio syndrome and related chronic pain. Methods: All subjects underwent a neurological examination including neuromuscular function, bedside sensory testing, a thorough pain anamnesis, and pain drawing. Screening for neuropathic pain was done with 2 questionnaires. A comprehensive Quantitative Sensory Testing battery was conducted with z-score transformation of obtained data, enabling comparison with published reference values and the creation of sensory profiles, as well as comparison between the study site (more polio affected extremity) and internal control site (less affected extremity) for each patient. Results: Derived sensory profiles showed signs of increased prevalence of sensory aberrations compared with reference values, especially Mechanical Pain Thresholds, with significant deviation from reference data in 5 out of 6 patients. No obvious differences in sensory functions were seen between study sites and internal control sites. Conclusion: Post-polio syndrome may be correlated with a mechanical hyperalgesia/allodynia and might be correlated to a somatosensory dysfunction. With lack of evident side-to-side differences, the possibility of a generalized dysfunction in the somatosensory system might be considered.

show abstract

Section: Discussionmentioning

confidence: 96%

Post-polio syndrome – somatosensory dysfunction and its relation to pain: a pilot study with quantitative sensory testing

Dahlgren,

Borg,

Melin

2024

JRM

View full text Add to dashboard Cite

show abstract

“…The scores of ≥ 4.0 for BASDAI and ≥ 2.1 for ASDAS–CRP were regarded as high-disease activity [ 12 , 18 ]. The disease activity indexes and the patient-reported outcomes at the time of the last visit, including ASDAS–ESR, Maastricht Enthesopathy Score (MASES; 1–10), the Bath Ankylosing Spondylitis Functional Index (BASFI; 1–10), the global VAS (1–100) for the patient, the physician, pain, and fatigue, the Disease Activity Index for Psoriatic Arthritis (DAPSA), the Psoriasis Area and Severity Score (PASI), the symptom severity score, fibromyalgia severity score, and tender, and swollen joint counts, were recorded [ 18 , 20 , 23 – 29 ].…”

Section: Methodsmentioning

confidence: 99%

“…The range is between zero (no symptoms) and 31 (most severe symptoms). A higher score is regarded as an approximate measure of fibromyalgia severity [ 29 ].…”

Section: Methodsmentioning

confidence: 99%

Cross-sectional analysis of cardiovascular disease and risk factors in patients with spondyloarthritis: a real-life evidence from biostar nationwide registry

Duruöz,

Bodur,

Ataman

et al. 2024

Rheumatol Int

View full text Add to dashboard Cite

The association between spondyloarthritis and cardiovascular (CV) diseases is complex with variable outcomes. This study aimed to assess the prevalence rates of CV diseases and to analyze the impact of CV risk factors on CV disease in patients with spondyloarthritis. A multi-center cross-sectional study using the BioSTAR (Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs Registry) database was performed on patients with spondyloarthritis. Socio-demographic, laboratory, and clinical data were collected. Patients with and without major adverse cardiovascular events (MACE) were grouped as Group 1 and Group 2. The primary outcome was the overall group’s prevalence rates of CV disease and CV risk factors. The secondary outcome was the difference in socio-demographic and clinical characteristics between the groups and predictive risk factors for CV disease. There were 1457 patients with a mean age of 45.7 ± 10.9 years. The prevalence rate for CV disease was 3% (n = 44). The distribution of these diseases was coronary artery disease (n = 42), congestive heart failure (n = 4), peripheral vascular disorders (n = 6), and cerebrovascular events (n = 4). Patients in Group 1 were significantly male (p = 0.014) and older than those in Group 2 (p < 0.001). There were significantly more patients with hypertension, diabetes mellitus, chronic renal failure, dyslipidemia, and malignancy in Group 1 than in Group 2 (p < 0.05). Smoking (36.7%), obesity (24.4%), and hypertension (13.8%) were the most prevalent traditional CV risk factors. Hypertension (HR = 3.147, 95% CI 1.461–6.778, p = 0.003), dyslipidemia (HR = 3.476, 95% CI 1.631–7.406, p = 0.001), and cancer history (HR = 5.852, 95% CI 1.189–28.810, p = 0.030) were the independent predictors for CV disease. A multi-center cross-sectional study using the BioSTAR (Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs Registry) database was performed on patients with spondyloarthritis. Socio-demographic, laboratory, and clinical data were collected. Patients with and without major adverse cardiovascular events (MACE) were grouped as Group 1 and Group 2. The primary outcome was the overall group’s prevalence rates of CV disease and CV risk factors. The secondary outcome was the difference in socio-demographic and clinical characteristics between the groups and predictive risk factors for CV disease. There were 1457 patients with a mean age of 45.7 ± 10.9 years. The prevalence rate for CV disease was 3% (n = 44). The distribution of these diseases was coronary artery disease (n = 42), congestive heart failure (n = 4), peripheral vascular disorders (n = 6), and cerebrovascular events (n = 4). Patients in Group 1 were significantly male (p = 0.014) and older than those in Group 2 (p < 0.001). There were significantly more patients with hypertension, diabetes mellitus, chronic renal failure, dyslipidemia, and malignancy in Group 1 than in Group 2 (p < 0.05). Smoking (36.7%), obesity (24.4%), and hypertension (13.8%) were the most prevalent traditional CV risk factors. Hypertension (HR = 3.147, 95% CI 1.461–6.778, p = 0.003), dyslipidemia (HR = 3.476, 95% CI 1.631–7.406, p = 0.001), and cancer history (HR = 5.852, 95% CI 1.189–28.810, p = 0.030) were the independent predictors for CV disease. The prevalence rate of CV disease was 3.0% in patients with spondyloarthritis. Hypertension, dyslipidemia, and cancer history were the independent CV risk factors for CV disease in patients with spondyloarthritis.

show abstract

“…However, we have recently demonstrated that fibromyalgia syndrome (FMS), which is a widespread chronic pain syndrome with somatic symptoms, is common in people with PPS. [ 8 ] Depending on the diagnostic criteria used, we found the prevalence of FMS to range from 15% to 35% in 60 people with PPS, which is higher than the prevalence in people with polio without PPS and in the general population. Moreover, coexisting FMS was found to correlate with more severe PPS symptoms, decreased quality of life (QoL), and more severe polio-related impairments.…”

Section: Introductionmentioning

confidence: 91%

“…The high prevalence of FMS that we reported recently also supports this assumption. [ 8 ] Therefore, our objectives were to investigate the presence and severity of CS in individuals with a history of poliomyelitis with and without PPS using the Central Sensitization Inventory (CSI), a valid and reliable scale to determine CS. [ 11 12 13 ] In addition, we evaluated whether CS was associated with the presence and severity of fatigue and pain, polio-related impairment, and QoL in people with PPS.…”

Section: Introductionmentioning

confidence: 99%

Prevalence and Severity of Central Sensitization in Post-Polio Syndrome: Associations with Clinical Measures and Quality of Life

On,

Latifoglou,

Çınar

et al. 2024

Annals of Indian Academy of Neurology

Self Cite

View full text Add to dashboard Cite

Objectives: To investigate the presence and severity of central sensitization (CS) and its associations with clinical measures and quality of life (QoL) in individuals with a history of paralytic poliomyelitis with and without post-polio syndrome (PPS). Methods: In this cross-sectional study, we included 98 individuals with a history of poliomyelitis, in whom 82 (83.6%) met the criteria of PPS. We used CS Inventory (CSI) to evaluate the presence and severity of CS. We evaluated the severity of fatigue, pain, polio-related impairments, and QoL using a Numerical Rating Scale in addition to Fatigue Severity Scale, Self-reported Impairments in Persons with late effects of Polio rating scale (SIPP), and Nottingham Health Profile (NHP). Results: CS was present in 52.4% of patients with PPS, of which 63% are classified as severe to extreme. Those with CS reported more severe symptoms, more polio-related impairments, and worse QoL than those without CS. Severity of CS showed significant positive correlations with severity of fatigue, pain, SIPP, and NHP scales in those with PPS. CSI did not indicate CS in any of those without PPS. Conclusion: CS was present in more than half of the individuals with PPS and correlated with more severe pain, fatigue, and more polio-related impairments, in addition to poorer QoL. These findings suggest that CS may contribute to the clinical picture in a subgroup of individuals with PPS. Thus, identification and appropriate management of CS patients may potentially help alleviate their symptoms and improve their QoL.

show abstract

Coexistence of fibromyalgia and post-polio syndrome in persons with prior poliomyelitis in Turkey: the relations with symptoms, polio-related impairments, and quality of life

Cited by 3 publications

References 49 publications

Post-polio syndrome – somatosensory dysfunction and its relation to pain: a pilot study with quantitative sensory testing

Post-polio syndrome – somatosensory dysfunction and its relation to pain: a pilot study with quantitative sensory testing

Cross-sectional analysis of cardiovascular disease and risk factors in patients with spondyloarthritis: a real-life evidence from biostar nationwide registry

Prevalence and Severity of Central Sensitization in Post-Polio Syndrome: Associations with Clinical Measures and Quality of Life

Contact Info

Product

Resources

About